Evidence map›Paper›PMID 25719196›Full record

ArticlePloS one2015

Whole genome sequencing based characterization of extensively drug-resistant Mycobacterium tuberculosis isolates from Pakistan.

Asho Ali, Zahra Hasan, Ruth McNerney, Kim Mallard, Grant Hill-Cawthorne, Francesc Coll, Mridul Nair, Arnab Pain, Taane G Clark, Rumina Hasan

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 108 citations in OpenAlex.

  1. Article
  2. Review
  3. Diversification of gene content in theMicrobiology spectrum · 2024
    Article
  4. Article
  5. Resistance to pyrazinamide inJournal of clinical tuberculosis and other mycobacterial diseases · 2024
    Article
  6. Article
  7. Article
  8. Distribution and origins ofMicrobial genomics · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 4 countries.

Asho AliDepartment of Pathology and Microbiology, Aga Khan University Hospital, Karachi, Pakistan; School of Nursing and Midwifery, The Aga Khan University Hospital, Karachi, Pakistan.
Zahra HasanDepartment of Pathology and Microbiology, Aga Khan University Hospital, Karachi, Pakistan.
Ruth McNerneyFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Kim MallardFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Grant Hill-CawthornePathogen Genomics Laboratory, King Abdullah University of Science and Technology (KAUST), Thuwal, Kingdom of Saudi Arabia; Sydney Emerging Infections and Biosecurity Institute and School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia.
Francesc CollFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Mridul NairPathogen Genomics Laboratory, King Abdullah University of Science and Technology (KAUST), Thuwal, Kingdom of Saudi Arabia.
Arnab PainPathogen Genomics Laboratory, King Abdullah University of Science and Technology (KAUST), Thuwal, Kingdom of Saudi Arabia.
Taane G ClarkFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Rumina HasanDepartment of Pathology and Microbiology, Aga Khan University Hospital, Karachi, Pakistan.
London School of Hygiene & Tropical Medicine · GBAga Khan University Hospital · PKKing Abdullah University of Science and Technology · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Improved molecular diagnostic methods for detection drug resistance in Mycobacterium tuberculosis (MTB) strains are required. Resistance to first- and second- line anti-tuberculous drugs has been associated with single nucleotide polymorphisms (SNPs) in particular genes. However, these SNPs can vary between MTB lineages therefore local data is required to describe different strain populations. We used whole genome sequencing (WGS) to characterize 37 extensively drug-resistant (XDR) MTB isolates from Pakistan and investigated 40 genes associated with drug resistance. Rifampicin resistance was attributable to SNPs in the rpoB hot-spot region. Isoniazid resistance was most commonly associated with the katG codon 315 (92%) mutation followed by inhA S94A (8%) however, one strain did not have SNPs in katG, inhA or oxyR-ahpC. All strains were pyrazimamide resistant but only 43% had pncA SNPs. Ethambutol resistant strains predominantly had embB codon 306 (62%) mutations, but additional SNPs at embB codons 406, 378 and 328 were also present. Fluoroquinolone resistance was associated with gyrA 91-94 codons in 81% of strains; four strains had only gyrB mutations, while others did not have SNPs in either gyrA or gyrB. Streptomycin resistant strains had mutations in ribosomal RNA genes; rpsL codon 43 (42%); rrs 500 region (16%), and gidB (34%) while six strains did not have mutations in any of these genes. Amikacin/kanamycin/capreomycin resistance was associated with SNPs in rrs at nt1401 (78%) and nt1484 (3%), except in seven (19%) strains. We estimate that if only the common hot-spot region targets of current commercial assays were used, the concordance between phenotypic and genotypic testing for these XDR strains would vary between rifampicin (100%), isoniazid (92%), flouroquinolones (81%), aminoglycoside (78%) and ethambutol (62%); while pncA sequencing would provide genotypic resistance in less than half the isolates. This work highlights the importance of expanded targets for drug resistance detection in MTB isolates.

Indexed as

Genome, BacterialAntitubercular AgentsBacterial ProteinsCatalaseDrug Resistance, BacterialExtensively Drug-Resistant TuberculosisMycobacterium tuberculosisOxidoreductasesPentosyltransferasesPolymorphism, Single NucleotideAntitubercular AgentsBacterial ProteinsCatalaseEmbB protein, Mycobacterium tuberculosisInhA protein, MycobacteriumkatG protein, Mycobacterium tuberculosisOxidoreductasesPentosyltransferases

Identifiers

PMID25719196
PMCPMC4342168
OpenAlexW2115294037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.